Amplia Therapeutics Limited (ASX:ATX)

Market Cap	20.95M
Revenue (ttm)	3.41M
Net Income (ttm)	-6.19M
Shares Out	387.95M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,467
Average Volume	533,731
Open	0.0510
Previous Close	0.0510
Day's Range	0.0500 - 0.0540
52-Week Range	0.0490 - 0.1800
Beta	0.77
RSI	37.36
Earnings Date	May 29, 2025

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating sol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATX

Financial Performance

In 2023, Amplia Therapeutics's revenue was 4.45 million, an increase of 274.34% compared to the previous year's 1.19 million. Losses were -4.50 million, -27.86% less than in 2022.